Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9062 |
High Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.8984 |
High Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.8788 |
High Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.8788 |
High Similarity |
NPD1613 |
Approved |
0.8561 |
High Similarity |
NPD3027 |
Phase 3 |
0.8561 |
High Similarity |
NPD4625 |
Phase 3 |
0.8527 |
High Similarity |
NPD4749 |
Approved |
0.8492 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.8346 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.8231 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.8222 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.8182 |
Intermediate Similarity |
NPD1511 |
Approved |
0.8134 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.8088 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.8069 |
Intermediate Similarity |
NPD1512 |
Approved |
0.8054 |
Intermediate Similarity |
NPD2801 |
Approved |
0.797 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.797 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7955 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.7933 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7895 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.7867 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7838 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7817 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7817 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7795 |
Intermediate Similarity |
NPD228 |
Approved |
0.7737 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7714 |
Intermediate Similarity |
NPD1558 |
Phase 1 |
0.7712 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7704 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7698 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7692 |
Intermediate Similarity |
NPD6671 |
Approved |
0.7655 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7638 |
Intermediate Similarity |
NPD3022 |
Approved |
0.7638 |
Intermediate Similarity |
NPD3021 |
Approved |
0.7603 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7597 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7561 |
Intermediate Similarity |
NPD1242 |
Phase 1 |
0.7538 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7536 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7532 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7517 |
Intermediate Similarity |
NPD7447 |
Phase 1 |
0.7517 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7517 |
Intermediate Similarity |
NPD3540 |
Phase 1 |
0.75 |
Intermediate Similarity |
NPD4750 |
Phase 3 |
0.7484 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7484 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7484 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7483 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7465 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7453 |
Intermediate Similarity |
NPD7054 |
Approved |
0.745 |
Intermediate Similarity |
NPD7213 |
Phase 3 |
0.745 |
Intermediate Similarity |
NPD7212 |
Phase 2 |
0.7448 |
Intermediate Similarity |
NPD3539 |
Phase 1 |
0.7426 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7413 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.7413 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.7407 |
Intermediate Similarity |
NPD7472 |
Approved |
0.74 |
Intermediate Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.7391 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7391 |
Intermediate Similarity |
NPD6696 |
Suspended |
0.7391 |
Intermediate Similarity |
NPD3225 |
Approved |
0.7389 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7386 |
Intermediate Similarity |
NPD4678 |
Approved |
0.7386 |
Intermediate Similarity |
NPD4675 |
Approved |
0.7376 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7362 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.736 |
Intermediate Similarity |
NPD940 |
Approved |
0.736 |
Intermediate Similarity |
NPD846 |
Approved |
0.7344 |
Intermediate Similarity |
NPD290 |
Approved |
0.7329 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.7319 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.7317 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7301 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7297 |
Intermediate Similarity |
NPD1652 |
Phase 2 |
0.7297 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7296 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7287 |
Intermediate Similarity |
NPD2684 |
Approved |
0.7286 |
Intermediate Similarity |
NPD6584 |
Phase 3 |
0.7279 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.7279 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.7279 |
Intermediate Similarity |
NPD1778 |
Approved |
0.7266 |
Intermediate Similarity |
NPD8651 |
Approved |
0.7266 |
Intermediate Similarity |
NPD968 |
Approved |
0.726 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.725 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7244 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7241 |
Intermediate Similarity |
NPD1607 |
Approved |
0.7239 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.723 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.7222 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7222 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7219 |
Intermediate Similarity |
NPD4357 |
Discontinued |
0.7214 |
Intermediate Similarity |
NPD2797 |
Approved |
0.7211 |
Intermediate Similarity |
NPD2796 |
Approved |
0.7205 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7197 |
Intermediate Similarity |
NPD7843 |
Approved |
0.7197 |
Intermediate Similarity |
NPD5535 |
Approved |
0.7185 |
Intermediate Similarity |
NPD5536 |
Phase 2 |
0.7179 |
Intermediate Similarity |
NPD37 |
Approved |
0.7172 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7169 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7169 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7164 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7162 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.7162 |
Intermediate Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.7161 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7152 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7152 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7152 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7143 |
Intermediate Similarity |
NPD4308 |
Phase 3 |
0.7143 |
Intermediate Similarity |
NPD7033 |
Discontinued |
0.7143 |
Intermediate Similarity |
NPD3748 |
Approved |
0.7133 |
Intermediate Similarity |
NPD3892 |
Phase 2 |
0.7124 |
Intermediate Similarity |
NPD1940 |
Clinical (unspecified phase) |
0.7117 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7114 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.7107 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7107 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7105 |
Intermediate Similarity |
NPD6799 |
Approved |
0.7103 |
Intermediate Similarity |
NPD1240 |
Approved |
0.7103 |
Intermediate Similarity |
NPD943 |
Approved |
0.7097 |
Intermediate Similarity |
NPD4005 |
Discontinued |
0.7086 |
Intermediate Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.7086 |
Intermediate Similarity |
NPD6190 |
Approved |
0.7083 |
Intermediate Similarity |
NPD8053 |
Approved |
0.7083 |
Intermediate Similarity |
NPD3268 |
Approved |
0.7083 |
Intermediate Similarity |
NPD8054 |
Approved |
0.7083 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.7075 |
Intermediate Similarity |
NPD4536 |
Approved |
0.7075 |
Intermediate Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.7075 |
Intermediate Similarity |
NPD4538 |
Approved |
0.7073 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7071 |
Intermediate Similarity |
NPD6582 |
Phase 2 |
0.7071 |
Intermediate Similarity |
NPD6583 |
Phase 3 |
0.7066 |
Intermediate Similarity |
NPD7549 |
Discontinued |
0.7063 |
Intermediate Similarity |
NPD1008 |
Clinical (unspecified phase) |
0.7059 |
Intermediate Similarity |
NPD4123 |
Phase 3 |
0.7059 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7055 |
Intermediate Similarity |
NPD5735 |
Approved |
0.7055 |
Intermediate Similarity |
NPD4340 |
Discontinued |
0.7051 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.705 |
Intermediate Similarity |
NPD3705 |
Approved |
0.7048 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7029 |
Intermediate Similarity |
NPD6516 |
Phase 2 |
0.7029 |
Intermediate Similarity |
NPD4626 |
Approved |
0.7029 |
Intermediate Similarity |
NPD5846 |
Approved |
0.7025 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7025 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.702 |
Intermediate Similarity |
NPD7466 |
Approved |
0.702 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7016 |
Intermediate Similarity |
NPD2934 |
Approved |
0.7016 |
Intermediate Similarity |
NPD2933 |
Approved |
0.7015 |
Intermediate Similarity |
NPD1398 |
Phase 1 |
0.7013 |
Intermediate Similarity |
NPD5261 |
Clinical (unspecified phase) |
0.7007 |
Intermediate Similarity |
NPD4097 |
Suspended |
0.7006 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7 |
Intermediate Similarity |
NPD1608 |
Approved |
0.7 |
Intermediate Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.6993 |
Remote Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.6985 |
Remote Similarity |
NPD7340 |
Approved |
0.6981 |
Remote Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.6981 |
Remote Similarity |
NPD5402 |
Approved |
0.6978 |
Remote Similarity |
NPD3496 |
Discontinued |
0.6975 |
Remote Similarity |
NPD6959 |
Discontinued |
0.6974 |
Remote Similarity |
NPD2677 |
Approved |
0.6974 |
Remote Similarity |
NPD2219 |
Phase 1 |
0.6968 |
Remote Similarity |
NPD5403 |
Approved |
0.6962 |
Remote Similarity |
NPD6801 |
Discontinued |
0.696 |
Remote Similarity |
NPD844 |
Approved |
0.696 |
Remote Similarity |
NPD2859 |
Approved |
0.696 |
Remote Similarity |
NPD2860 |
Approved |
0.6957 |
Remote Similarity |
NPD1357 |
Approved |
0.6954 |
Remote Similarity |
NPD3060 |
Approved |
0.6944 |
Remote Similarity |
NPD5752 |
Clinical (unspecified phase) |
0.6939 |
Remote Similarity |
NPD6355 |
Discontinued |
0.6939 |
Remote Similarity |
NPD447 |
Suspended |
0.6937 |
Remote Similarity |
NPD7768 |
Phase 2 |
0.6933 |
Remote Similarity |
NPD5763 |
Approved |
0.6933 |
Remote Similarity |
NPD5762 |
Approved |
0.6929 |
Remote Similarity |
NPD3020 |
Approved |
0.6929 |
Remote Similarity |
NPD1611 |
Approved |
0.6928 |
Remote Similarity |
NPD5058 |
Phase 3 |
0.6928 |
Remote Similarity |
NPD7124 |
Phase 2 |
0.6918 |
Remote Similarity |
NPD2674 |
Phase 3 |
0.6918 |
Remote Similarity |
NPD6233 |
Phase 2 |
0.6914 |
Remote Similarity |
NPD5494 |
Approved |
0.6913 |
Remote Similarity |
NPD5960 |
Phase 3 |
0.6913 |
Remote Similarity |
NPD6029 |
Clinical (unspecified phase) |
0.6913 |
Remote Similarity |
NPD5588 |
Approved |
0.6913 |
Remote Similarity |
NPD6028 |
Clinical (unspecified phase) |
0.6908 |
Remote Similarity |
NPD6331 |
Phase 2 |
0.6901 |
Remote Similarity |
NPD2922 |
Phase 1 |
0.6899 |
Remote Similarity |
NPD7411 |
Suspended |
0.6899 |
Remote Similarity |
NPD6072 |
Discontinued |
0.6899 |
Remote Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.6883 |
Remote Similarity |
NPD7837 |
Clinical (unspecified phase) |
0.6879 |
Remote Similarity |
NPD6055 |
Clinical (unspecified phase) |
0.6875 |
Remote Similarity |
NPD6374 |
Clinical (unspecified phase) |
0.6871
|
Remote Similarity |
NPD2238 |
Phase 2 |